Literature DB >> 34407055

HMGA1 promotes hepatocellular carcinoma proliferation, migration, and regulates cell cycle via miR-195-5p.

Minyang Shi1, Xuyang Lv, Mengqi Zhu, Yue Dong, Linfeng Hu, Ying Qian, Chunlei Fan, Nan Tian.   

Abstract

HMGA1 has been reported to be aberrantly expressed and correlate with the poor prognosis of many carcinomas. This study aimed to investigate the clinical significance and molecular mechanism of HMGA1 as a tumor-suppressing gene in hepatocellular carcinoma (HCC). Analysis of TCGA dataset by TANRIC website and R2 platform, we found that HMGA1 expression was significantly higher in HCC tissues compared to that in normal liver tissues and was associated with Edmondson grade. Patients with highly expressed HMGA1 had worse overall survival. Gene ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes analysis showed the potential relationships between HMGA1 and other genes in HCC. We also demonstrated that the downregulation of HMGA1 dramatically suppressed the proliferation and migration of HCC cells. Furthermore, ectopic expression of HMGA1 blocked G0/G1 to S transition. Subsequent investigation characterized HMGA1 as a direct target of miR-195-5p, and miR-195-5p downregulation abrogated the effect of HMGA1 on HCC proliferation, migration, and cell cycle arrest. In addition, we also demonstrated that miR-195-5p downregulation abrogated the effect of HMGA1 on HCC growth in vivo. Taken together, our data provide strong evidence that HMGA1 promotes HCC and is negatively regulated by the tumor-suppressor, miR-195-5p.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34407055     DOI: 10.1097/CAD.0000000000001201

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

Review 1.  High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.

Authors:  Lu Wang; Ji Zhang; Min Xia; Chang Liu; Xuyu Zu; Jing Zhong
Journal:  Int J Biol Sci       Date:  2022-07-04       Impact factor: 10.750

2.  miR‑4730 suppresses the progression of liver cancer by targeting the high mobility group A1 pathway.

Authors:  Hirotaka Furuke; Hirotaka Konishi; Tomohiro Arita; Satoshi Kataoka; Jun Shibamoto; Kazuya Takabatake; Wataru Takaki; Hiroki Shimizu; Yusuke Yamamoto; Ryo Morimura; Shuhei Komatsu; Atsushi Shiozaki; Hisashi Ikoma; Eigo Otsuji
Journal:  Int J Mol Med       Date:  2022-04-29       Impact factor: 5.314

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.